Semaglutide, marketed as Ozempic, recently became the first glucagon-like peptide 1 (GLP-1) receptor agonist approved by the US Food and Drug Administration (FDA) to reduce

Related Stocks: OTCPK:LTNC,

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says.

A new study published in Nature offers the most detailed map to date of how individual cell types in the brain change with age. Scientists

[/boxout] Vomiting Both Stephen Fry and Boris Johnson have admitted to vomiting while trying to shed weight with the jabs. Stephen Fry was left vomiting

By Dennis Thompson HealthDay ReporterTUESDAY, April 1, 2025 (HealthDay News) — The number of Americans taking cutting-edge weight-loss drugs like…

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company’s sales surged 32% to over $45 billion on massive growth from

A nurse has revealed exactly what you need to be drinking when you’re on a GLP-1 medication – and why hydration on the medication is

Obesity remains highly prevalent among children in the United States and is associated with an ever-increasing burden of obesity-related diseases. Effective pediatric obesity prevention and

What You Should Know:  – Noom, a digital healthcare company focused on chronic disease prevention and empowering healthy living announced an agreement with Gifthealth, the

(MedPage Today) — The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual spending from

Background: Obesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and type 2 diabetes in

Novo Nordisk’s Monthly Share Plunge Largest Since Dot Com Bust Novo Nordisk A/S shares are on track for their steepest monthly decline since the Dot-Com

GLP-1 medications are reshaping the weight management landscape — and beginning to take a bite out of bariatric surgery volumes in hospitals.  Between 2022 and

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement,

UK-based wellness brand Elénzia is expanding its supplement portfolio with a new product for appetite control and blood sugar regulation.

The FDA has accepted Novo Nordisk’s application for a label expansion for oral GLP-1 treatment Rybelsus to reduce the risk of major adverse cardiovascular events

ANN ARBOR, Mich.–(BUSINESS WIRE)–ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new

Linda Bethea details how the marketer of brands including Oikos and Silk is approaching emerging channels and artificial intelligence.

Related Stocks: AMEX:PTN,

CEO Wendy Davidson said the Sleepytime Tea maker needed to first stabilize its business and boost innovation before it could tap into movements such as GLP-1

IntroductionKidney allograft fibrosis accelerates the progression of chronic kidney disease (CKD), leads to allograft failure, and increases patient mortality. Emerging evidence suggests that metabolic syndrome